FDA's Great(er) Expectations: Avoiding a Refuse-to-File in a New Review Environment
This article was originally published in RPM Report
Each year, FDA rejects just a handful of new drug and biologics applications that aren’t quite complete enough for review. Now the agency’s revamped review process is forcing its staff to take a closer, earlier look at new submissions. Merck’s Zetia/Lipitor "refuse to file" letter is a case in point. Unless things improve, Office of New Drugs Director John Jenkins says, industry can expect more early rejections from FDA.
You may also be interested in...
Technical deficiencies foil the resubmission of Chelsea Therapeutics’ Northera. The company thinks it can resolve the problems quickly and some analysts expect a relatively short delay of one or two months to the user fee date.
A negative, head-to-head study questioning the role of Vytorin is presented at AHA: that sounds like a replay of the ENHANCE disaster. But here's the twist: Merck shares rallied after the data were released. What changed?
There are changes coming to FDA's drug review process that, over the long term, should make the system more predictable and increase the chances for a first-cycle approval. Until then, expect a less forgiving agency when it comes to incomplete submissions-and challenges that may threaten the sanctity of priority reviews.